Swedish Orphan Biovitrum AB
https://www.sobi.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Swedish Orphan Biovitrum AB
AbbVie Extends Reach Of Regenxbio’s Wet AMD Program
The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.
Apellis Says Mixed Phase III Results Position Geographic Atrophy Candidate For Filing
Apellis plans to file pegcetacoplan for approval as the first drug to treat the advanced AMD condition geographic atrophy, despite the C3 inhibitor hitting its endpoint in only one of two pivotal trials.
COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.
Sobi To Go Private In $8.1bn Buyout That Appreciates Growth Strategy
Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Akinion Pharmaceuticals AB
- Arexis AB
- Biovitrum AB
- Dova Pharmaceuticals, Inc.
- Sobi, Inc.
- Swedish Orphan International Holding AB